Smallcap pharma company Windlas Biotech Limited approved a comprehensive share buyback worth ₹470 crore on Friday, April 17, 2026, according to regulatory filings to stock exchanges under Regulation 30 and Regulation 42 of SEBI LODR Regulations. The company will purchase 4.7 lakh equity shares from existing investors at ₹1,000 per share through the tender offer route. The buyback represents 2.23% of the company's equity and will be executed in accordance with Securities and Exchange Board of India (Sebi) regulations. The buyback will be conducted at a price of ₹1,000 per equity share, payable in cash, representing 9.80% of the aggregate total paid-up equity share capital and free reserves based on audited financial statements as at March 31, 2025.
Following the buyback announcement, Windlas Biotech shares jumped 2% to hit the day's high of ₹887 on the NSE, as reported by ETMarkets.com. The stock has demonstrated strong performance over the longer term, rallying over 20% over a one-year period. However, shares have been market underperformers, sliding over 18% in the past 12 months, while Nifty's one-year returns in the same period are 4% and BSE Sensex returns are 2%.
The total buyback size constitutes 9.8% of the company's paid-up equity capital and free reserves, based on its latest audited financials as of March 31, 2025, according to the regulatory filings. The offer is open to all eligible public shareholders, while promoters and promoter group entities have expressed their intention not to participate. As per regulatory norms, 15% of the buyback size will be reserved for small shareholders, ensuring wider retail participation in the capital return program. The buyback will be conducted through the "Tender Offer" route as prescribed under SEBI Buy-Back Regulations, 2018, with the board retaining flexibility to increase the buyback price and decrease the number of shares till one working day prior to the record date.
The company has fixed April 24, 2026, as the record date to determine shareholder eligibility for the buyback, as reported by the regulatory filings. Windlas Biotech has constituted a buyback committee with delegated powers to execute all necessary actions for the buyback process. Mr. Ananta Narayan Panda, Company Secretary, has been appointed as the Compliance Officer for the proposed buyback. Fintellectual Corporate Advisors Private Limited, a SEBI registered merchant banker, has been appointed as the Manager to the Buyback. The board retains the flexibility to revise the buyback price upward while proportionately reducing the number of shares, without altering the overall buyback size.
As of March 31, 2026, the company's pre-buyback shareholding structure shows promoters and promoter group holding 1,30,65,352 shares representing 61.90% of the total paid-up capital. The total number of shareholders stands at 44,769 with 2,11,06,229 equity shares outstanding. Shareholder category-wise distribution includes Resident Individuals (up to ₹2 lakhs): 41,11,525 shares (19.48%) and Mutual Funds: 14,94,421 shares (7.08%). The company has also scheduled a virtual group meeting with analysts and institutional investors for April 20, 2026, at 3:00 PM, notifying stock exchanges on April 15, 2026, in compliance with SEBI Regulation 30(6) requirements.
